
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is a fully integrated CDMO that has displayed strong commercial momentum in recent months with several new agreements signed with global pharmaceutical companies, including a new agreement for technical transfer services in the manufacturing of an injectable suspension product for neurological disorders. The company's turnaround phase under CEO Paul Josephs has been completed, and management has stated that it now has the necessary resources to execute its strategic vision. With over 30 active projects in its pipeline, including late-stage and commercial site transfers, Lifecore is expected to see significant revenue growth starting in 2028, with some impact potentially being felt in 2027. Although there are risks to consider, such as failing to meet revenue or earnings estimates, we maintain our OUTPERFORM rating and have increased our 12-month price target to $6.50.
Bears say
Lifecore Biomedical is struggling with significant leverage and a low cash flow, which may impact their ability to handle future tech transfer wins and hinder their potential for growth in the long term. However, the company's leadership has provided some reassurance by affirming their financial guidance, which includes a projected increase in capacity utilization and margin on incremental revenue. These efforts could potentially offset the negative impact of their current financial situation over time.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares